Affinium Pharmaceuticals of Toronto has appointed new senior directors in chemistry and structural biology, and has promoted three existing senior executives: Klaus Fiebig will be the company’s new senior director of structural biology, leading its efforts in X-ray crystallography and NMR. Fiebig comes to Affinium from MRPharm of Frankfurt, Germany, where he was CEO and a co-founder. He holds a PhD in pharmaceutical chemistry from the University of California, San Francisco. Henry Pauls is the company’s new senior director of medicinal chemistry.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.